Product Description
Moleculin's WP1220 (aka MOL4239) has data demonstrating significant activity in preclinical studies and is being studied as a possible topical treatment for CTCL. (Sourced from: https://ir.moleculin.com/press-releases/detail/37/moleculin-announces-preparation-to-file-an-ind-with-the-fda)
Mechanisms of Action: STAT3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Moleculin
Company Location: HOUSTON TX 77007
Company CEO: Walter V. Klemp
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| M-02 | P2 |
Completed |
Psoriasis |
2013-08-01 |